Janux plans first JANX011 safety update in healthy volunteers by year-end
The Phase 1 trial testing Janux's CD19-directed ARM molecule in healthy adults is recruiting toward an October 2026 primary completion, with an initial update guided for the second half of the year.
Executive Summary
- Janux Therapeutics is on track to disclose an initial safety update from its first human study of a CD19-directed autoimmune candidate, a platform distinct from its prostate-cancer engineered T-cell franchise.
- Because the study enrolls healthy volunteers rather than patients, the update will establish tolerability, not clinical benefit, and any advance into autoimmune disease will depend on that safety read.
- The trial has progressed from not-yet-recruiting to actively recruiting on an unchanged enrollment target and a stable protocol, indicating the study is proceeding on its original design rather than under operational strain.
- No other industry-sponsored trial shares this molecule's CD19-targeted immunomodulator mechanism in a healthy-volunteer safety setting, leaving the update as the first data point for this approach rather than one benchmarked against a direct rival.
The catalyst
Janux said in its first-quarter 2026 update that it "plans to announce an initial clinical update from the Phase 1 study of JANX011 in healthy volunteers in the second half of 2026". The update is tied to NCT07291323, an Early Phase 1 study enrolling healthy adult volunteers in Australia to assess safety and tolerability of JANX011, described internally as a CD19-ARM molecule. Janux CEO David Campbell said the study "has been designed to support our emerging autoimmune disease opportunity", distinguishing it from the company's PSMA-targeted TRACTr programs in prostate cancer. Janux+1Janux Therapeutics Reports First Quarter 2026 Financial Results and Business HighlightsMay 7, 2026Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.NCT07291323
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial tests
The registered primary endpoint is the incidence, severity, and relatedness of treatment-emergent adverse events, serious adverse events, and adverse events of special interest. That is a safety and tolerability design, not an efficacy measure: the trial cannot establish whether JANX011 works in autoimmune disease, only whether the molecule is tolerated in healthy adults dosed subcutaneously or intravenously. The study targets 60 participants, first dosed a participant on February 17, 2026, and carries a primary completion date of October 1, 2026. NCT07291323Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.NCT07291323
Operational footing
The trial's status moved from Not yet recruiting to Recruiting on April 23, 2026. Its enrollment target has held flat at 60 participants with no amendment to the protocol, and the operational risk model flags the trial as within its typical enrollment band, since the model's threshold for a notable enrollment shift is a change of 20% or more. The registry shows a single status change and no endpoint or completion-date amendments since the study was first posted on December 18, 2025. That is a normal early-stage trajectory, not a signal of strain. NCT07291323Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.NCT07291323
The competitive frame
No industry-sponsored trial in the broader autoimmune-disease landscape shares JANX011's CD19-directed immunomodulator mechanism paired with a healthy-volunteer safety design. The nearest trials in the same indication family test different mechanisms entirely, including CAR-T cell therapies targeting CD19 in patient populations, an IL-2 receptor agonist, and an IMPDH2 inhibitor, none of which share JANX011's modality or its healthy-volunteer testing population. That mechanistic isolation means the update carries no resolved same-class precedent to benchmark against; it will be read on its own tolerability signal rather than against a comparator track record.
What the update would need to show
With no validated safety precedent for a CD19-directed ARM molecule in this setting, the informative result is a clean adverse-event profile across the dose range tested, without dose-limiting toxicities that would slow escalation toward a patient study. Because the design measures only safety and tolerability, a clean AE profile would open the door to a patient-population trial in autoimmune disease; it would not by itself demonstrate that the mechanism has clinical effect. NCT07291323Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.NCT07291323
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.